Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp16710_8k.htm |
Exhibit
99.01
|
Press Release
www.shire.com
|
 |
Director/PDMR
Shareholding
March 3, 2010 - Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on March 1,
2010 the following Persons Discharging Managerial Responsibility (“PDMRs”) were
granted awards under the Shire Portfolio Share Plan (the “Plan”).
Awards
of Stock Appreciation Rights (“SARs”) under Part A of the Plan
|
Name
of PDMR
|
Type
of Security
|
No
of Ordinary Shares or ADSs
|
Exercise
price
|
||
|
Angus Russell
(Executive Director)*
|
ADSs
|
105,616
|
$64.91
|
||
|
Graham
Hetherington (Executive Director)*
|
Ordinary
Shares
|
134,814
|
£14.43
|
||
|
Tatjana
May
|
Ordinary
Shares
|
38,000
|
£14.43
|
||
|
Michael
Cola
|
ADSs
|
20,000
|
$64.91
|
||
|
Sylvie
Gregoire
|
ADSs
|
20,000
|
$64.91
|
||
|
Barbara
Deptula
|
ADSs
|
12,333
|
$64.91
|
||
|
Anita
Graham
|
ADSs
|
11,333
|
$64.91
|
*Vesting of awards
to Executive Directors is subject to performance targets
SARs will normally
vest after three years, subject to any performance targets having been
satisfied. Vested SARs will be capable of exercise for a period of
four years. The four year exercise period is subject to shareholder
approval at Shire plc’s 2010 Annual General Meeting. Should such
approval not be obtained, the exercise period will be two years. No
consideration was paid for the grant of the SARs.
Performance
Share Awards (“PSA Awards”) under Part B of the Plan
|
Name
of PDMR
|
Type
of Security
|
No
of Ordinary Shares or ADSs
|
Market
value
|
||
|
Angus Russell
(Executive Director)*
|
ADSs
|
73,948
|
$64.91
|
||
|
Graham
Hetherington (Executive Director)*
|
Ordinary
Shares
|
98,864
|
£14.43
|
||
|
Tatjana
May
|
Ordinary
Shares
|
28,000
|
£14.43
|
||
|
Michael
Cola
|
ADSs
|
15,000
|
$64.91
|
||
|
Sylvie
Gregoire
|
ADSs
|
15,000
|
$64.91
|
||
|
Barbara
Deptula
|
ADSs
|
9,000
|
$64.91
|
||
|
Anita
Graham
|
ADSs
|
8,000
|
$64.91
|
*Vesting of awards
to Executive Directors is subject to performance targets
The PSA Awards will
normally vest after three years, subject to any performance targets being
satisfied. Once vested, sufficient ordinary shares or ADSs will be
transferred or allotted to the participant within 30 days. No
consideration was paid for the grant of the PSA Awards.
Registered in Jersey, No. 99854,
22 Grenville
Street, St Helier,
Jersey JE4 8PX
This notification
is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure
and Transparency Rules.
Tony
Guthrie
Deputy Company
Secretary
For
further information please contact:
|
Investor
Relations
|
Cléa
Rosenfeld (Rest of the World)
|
+44 1256 894
160
|
|
Eric Rojas
(North America)
|
+1 617 551
9715
|
Notes
to editors
SHIRE
PLC
Shire’s strategic
goal is to become the leading specialty biopharmaceutical company that focuses
on meeting the needs of the specialist physician. Shire focuses its
business on attention deficit hyperactivity disorder (ADHD), human genetic
therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in
other therapeutic areas to the extent they arise through
acquisitions. Shire’s in-licensing, merger and acquisition efforts
are focused on products in specialist markets with strong intellectual property
protection and global rights. Shire believes that a carefully
selected and balanced portfolio of products with strategically aligned and
relatively small-scale sales forces will deliver strong results.
For further
information on Shire, please visit the Company’s website: www.shire.com.